- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00784875
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia (SLUMBER)
January 30, 2012 updated by: Eli Lilly and Company
A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study of the Safety and Efficacy of LY2624803 in Outpatients With Insomnia
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Outpatients with chronic insomnia who participate in this study will be treated in each of four 2-week treatment periods with bedtime doses of either placebo, zolpidem, LY2624803 1 mg, or LY2624803 3 mg.
Neither patients nor investigators will be told what treatments are being given in any treatment period.
A patient who completes all four treatment periods will be treated with placebo in 1, 2, or 3 of the periods; with zolpidem in 0, 1, or 2 of the periods; and with LY2624803 in either 1 or 2 of the periods.
No patient will receive placebo for all four of the 2-week treatment periods.
All patients will receive LY2624803 for at least one of the four 2-week treatment periods.
During each treatment period, patients will record information each morning about their sleep the night before, and each evening about their functioning since waking up.
Patients will also wear wrist actigraphy devices to record their physical activity.
At the conclusion of each treatment period, patients will answer questions about their sleep, functioning, health, and relative preference for treatments.
Study Type
Interventional
Enrollment (Actual)
643
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35213
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Arizona
-
Glendale, Arizona, United States, 85306
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mesa, Arizona, United States, 85210
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
California
-
Burbank, California, United States, 91505
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Glendale, California, United States, 91206
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Los Angeles, California, United States, 90048
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Oceanside, California, United States, 92056
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Pismo Beach, California, United States, 93449
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
San Diego, California, United States, 92123
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Santa Rosa, California, United States, 95405
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Torrance, California, United States, 90502
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Colorado
-
Denver, Colorado, United States, 80239
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Florida
-
Fruitland Park, Florida, United States, 34731
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Hialeah, Florida, United States, 33012
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Lauderdale Lakes, Florida, United States, 33319
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Maitland, Florida, United States, 32751
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Naples, Florida, United States, 34110
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Pembroke Pines, Florida, United States, 33024
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
St Petersburg, Florida, United States, 33707
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Tampa, Florida, United States, 33607
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Suwanee, Georgia, United States, 30024
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Illinois
-
Oak Brook, Illinois, United States, 60523
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Springfield, Illinois, United States, 62711
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Indiana
-
Terre Haute, Indiana, United States, 47802
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Kentucky
-
Crestview Hills, Kentucky, United States, 41017
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Massachusetts
-
Wellesley Hills, Massachusetts, United States, 02481
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Michigan
-
Sterling Heights, Michigan, United States, 48314
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Missouri
-
Florissant, Missouri, United States, 63033
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Nevada
-
Las Vegas, Nevada, United States, 89146
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
New York
-
Bronx, New York, United States, 10454
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Brooklyn, New York, United States, 11235
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
North Carolina
-
Hickory, North Carolina, United States, 28601
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Raleigh, North Carolina, United States, 27612
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Winston-Salem, North Carolina, United States, 27103
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Ohio
-
Cincinnati, Ohio, United States, 45246
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cleveland, Ohio, United States, 44122
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Oregon
-
Portland, Oregon, United States, 97210
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, United States, 19046
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Rhode Island
-
Lincoln, Rhode Island, United States, 02865
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Texas
-
Austin, Texas, United States, 78756
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Dallas, Texas, United States, 75231
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
San Antonio, Texas, United States, 78229
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Washington
-
Bellevue, Washington, United States, 98004
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Lakewood, Washington, United States, 98499
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be between 18 and 85 years of age, with a stable living situation
- Clinical diagnosis of either primary insomnia or "secondary" insomnia (comorbid with depression, anxiety, and/or medical illness)
- Insomnia systems must be at least moderate in severity within the month prior to study entry, and must include difficulty staying asleep and/or problems with awakening earlier than desired
- Psychiatric and medical conditions present must be stable over the 3 months prior to study entry, and not expected to worsen significantly or require hospitalization during participation in the study
- Ongoing treatments for psychiatric and medical conditions present must have been stable for the 3 months prior to study entry, and must be expected to remain stable during participation in the study
- Patients must be willing to abstain from taking medications (other than study drug) to help them sleep during participation in the study
- Patients must be willing to consistently spend at least 7 hours each night either sleeping or trying to sleep during participation in the study
- Patients must be able to speak and read English and be capable of using a computer with a web browser (computers with internet connections will be provided to patients who need them)
Exclusion Criteria:
- Unusual or unstable sleep/wake schedule, such as with rotating shift work
- Severe or unstable psychiatric or medical illness
- Suicidal ideation
- Substance abuse
- Known obstructive sleep apnea, restless leg syndrome, or periodic limb movement disorder
- History of seizures
- Body Mass Index > 33
- Clinically significant abnormality in clinical chemistry, hematology, urinalysis, and/or electrocardiogram
- Anticipated inability to regularly use a medication which might reduce motor or cognitive functioning during sleeping hours, such as a person who might often need to be "on call", drive a car, or be responsible for the care of another person during sleeping hours
- Contraindication to zolpidem
- History of breast cancer
- An estimated glomerular filtration rate (GFR; an index of renal function) that is <30 mL/min at study entry
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Period A
2-week double-blind placebo lead-in period.
Period A is the first of four 2-week treatment periods.
|
matching placebo (capsule or tablet), once nightly before bedtime
|
Experimental: Period B
Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods.
Period B is the second of four 2-week treatment periods.
|
matching placebo (capsule or tablet), once nightly before bedtime
1 mg, oral capsule, once nightly before bedtime
3 mg, oral capsule, once nightly before bedtime
5 or 10 mg, oral tablet, once nightly before bedtime
|
Experimental: Period C
Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods.
Period C is the third of four 2-week treatment periods.
|
matching placebo (capsule or tablet), once nightly before bedtime
1 mg, oral capsule, once nightly before bedtime
3 mg, oral capsule, once nightly before bedtime
5 or 10 mg, oral tablet, once nightly before bedtime
|
Experimental: Period D
Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods.
Period D is the fourth of four 2-week treatment periods.
|
matching placebo (capsule or tablet), once nightly before bedtime
1 mg, oral capsule, once nightly before bedtime
3 mg, oral capsule, once nightly before bedtime
5 or 10 mg, oral tablet, once nightly before bedtime
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
Total Sleep Time is defined as time in bed minus total time awake.
Minimum would be 0; no defined maximum (except if as defined as time in bed).
The higher the number, the more time asleep.
Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks).
Change score subtracts Period B average from Period A average (baseline).
Analysis of covariance (ANCOVA) Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Unwanted Time Awake at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
Unwanted time awake (minutes awake [MA] before sleep [between turning off the lights to first falling asleep], MA during sleep, MA after sleep before getting out of bed).
Minimum would be 0; no defined maximum.
The higher the number, the more the unwanted time awake.
Calculated in minutes from participant-reported daily sleep questionnaire averaged (Avg.)
across Period B. Change score subtracts Period B Avg. from Period A Avg. (baseline).
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group, and insomnia type.
|
Baseline, 2 weeks
|
Change From Baseline in Number of Awakenings During Sleep at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
Elicited from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks).
Change score subtracts Period B average from Period A average (baseline).
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Change From Baseline in Total Time Awake at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks).
Change score subtracts Period B average from Period A average (baseline).
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Change From Baseline in Sleep Efficiency at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
Calculated as (TIB-TTA)/TIB where TIB is time in bed and TTA is total unwanted time awake.
Higher score indicates better sleep efficiency.
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Change From Baseline in Assessment of Sleep Quality at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
Assessment of Sleep Quality (ASQ) scale is asked in the participant-reported daily sleep questionnaire; 8 items on 4 point Likert scale with a range of 0 to 24.
Sleep experience score ranges from 0-9; awakening experience ranges from 0-15.
The higher the score, the better the sleep.
Scale is averaged across study Period B (2 weeks).
Change score subtracts Period B average from Period A average (baseline).
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Change From Baseline in Participants' Impression of Daytime Functioning Measured by Daily Consequences of Insomnia Questionnaire (DCIQ) at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
DCIQ scale is asked in the participant-reported daily evening questionnaire; 5 point Likert scale with minimum of 0 and maximum of 44 (the higher the score, the more consequences of insomnia).
Scale is averaged across study Period B (2 weeks).
Change score subtracts Period B average from Period A average (baseline).
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Change From Baseline in the Insomnia Severity Index (ISI) at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
The ISI is a brief self-report instrument that measures a participant's perception of his or her insomnia.
7 questions on 5-point Likert scale with minimum of 0 and maximum of 28.
The higher the score, the more severe the insomnia.
It was collected at the bi-weekly office visits.
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Change From Baseline in Physical and Mental Component Scores as Measured by the Short Form 12 (SF-12) Version 2 at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
The SF-12 is a subset of 12 items from the Medical Outcomes Study 36-Item Short Form Survey (SF-36) and was collected at the bi-weekly office visits.
Each score ranges from 0-100.
The components measure physical and mental health, respectively.
Higher scores are indicative of better function.
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary)
|
Baseline, 2 weeks
|
Change From Baseline in Health-related Quality of Life as Measured by European Quality of Life (EuroQol) at Week 4 (Week 2 of Period B) Endpoint
Time Frame: Baseline, 2 weeks
|
The EuroQoL Questionnaire-5 Dimension (EQ-5D) is a generic, multidimensional, health-related, quality-of-life instrument.
The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood.
The score ranges 0-100.
The higher score indicates a better health state perceived by the participant.
ANCOVA Model with dependent variable being change from baseline scores and independent variables being treatment, baseline, age group (<65 or ≥65), and insomnia type (primary vs. secondary).
|
Baseline, 2 weeks
|
Treatment Satisfaction as Measured by the Participant Drug Preference Question
Time Frame: Baseline (Period A) and 2 weeks (Period B)
|
After study Periods A, and B, participants were asked to rate their experience with the treatment they had just completed.
Data are presented as percentage of participants preferring the treatment received in Period A (placebo) or treatment received in Period B.
|
Baseline (Period A) and 2 weeks (Period B)
|
Clinical Global Impression of Improvement (CGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint
Time Frame: 2 weeks
|
Measures clinician's perception of participant improvement at the time of assessment compared with the start of treatment.
Scores range from 1 (very much improved) to 7 (very much worse).
Data are presented as percentage of participants in each category.
|
2 weeks
|
Patient Global Impression of Improvement (PGI-I) in Insomnia at Week 4 (Week 2 of Period B) Endpoint
Time Frame: 2 weeks
|
A scale that measures the participant's perception of improvement at the time of assessment compared with the start of treatment.
The score ranges from 1 (very much improved) to 7 (very much worse).
Data are presented as percentage of participants in each category.
|
2 weeks
|
Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Insomnia Type
Time Frame: Baseline, 2 weeks
|
Total Sleep Time is defined as time in bed minus total time awake.
Minimum would be 0; no defined maximum (except if as defined as time in bed).
The higher the number, the more time asleep.
Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.
|
Baseline, 2 weeks
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Insomnia Type
Time Frame: Baseline through 8 weeks
|
Number of participants with AEs and SAEs.
Analyses were not performed by insomnia type (primary versus secondary) as originally planned because of insufficient number of secondary insomnia participants.
|
Baseline through 8 weeks
|
Change From Baseline in Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint Based on Age Group
Time Frame: Baseline, 2 weeks
|
Total Sleep Time is defined as time in bed minus total time awake.
Minimum would be 0; no defined maximum (except if as defined as time in bed).
The higher the number, the more time asleep.
Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.
|
Baseline, 2 weeks
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on Age Group
Time Frame: Baseline through 8 weeks
|
Number of participants with AEs and SAEs.
Analyses were not performed by age group (under age 65 versus over age 65) as originally planned because of insufficient number of elderly participants.
|
Baseline through 8 weeks
|
Number of Participants With Treatment Emergent Adverse Events (TEAE)
Time Frame: Baseline through 8 weeks
|
Treatment Emergent Adverse Events (TEAEs) are defined as AEs that first occurred or worsened during the treatment period.
TEAEs are summarized by study period and treatment group.
TEAEs do not distinguish whether the events were deemed serious.
A summary of non-serious AEs is located in the Reported Adverse Event module.
|
Baseline through 8 weeks
|
Number of Participants With Serious Adverse Events (SAEs)
Time Frame: Baseline through 8 weeks
|
SAEs do not distinguish whether the events are treatment-emergent.
A summary of SAEs is located in the Reported Adverse Event module.
|
Baseline through 8 weeks
|
Change From Baseline in Blood Pressure (BP) at Each 2-Week Treatment Endpoint
Time Frame: Baseline, 2 weeks of treatment over 8 weeks
|
Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for systolic blood pressure (SBP) and diastolic blood pressure (DBP) are presented.
Least Squares Mean (LSMean) values were adjusted for baseline and treatment.
|
Baseline, 2 weeks of treatment over 8 weeks
|
Change From Baseline in Pulse Rate at Each 2-week Treatment Endpoint
Time Frame: Baseline, 2 weeks of treatment over 8 weeks
|
Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for pulse rate are presented.
Least Squares Mean (LSMean) values were adjusted for baseline and treatment.
|
Baseline, 2 weeks of treatment over 8 weeks
|
Change From Baseline in Weight at Each 2-week Treatment Endpoint
Time Frame: Baseline, 2 weeks of treatment over 8 weeks
|
Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for body weight are presented.
Least Squares Mean (LSMean) values were adjusted for baseline and treatment.
|
Baseline, 2 weeks of treatment over 8 weeks
|
Number of Participants With Abnormal Laboratory Analytes at Each 2-Week Treatment Endpoint
Time Frame: 2 weeks of treatment over 8 weeks
|
Summary of number of participants with abnormal clinical chemistry, hematology and urinalysis laboratory results.
A participant is included in the abnormal category if he/she experienced a result outside the normal reference ranges based on Lilly's reference range in the current period.
All analytes have both lower and upper limits.
The abnormal number includes both low (below normal range) and high (above normal range).
|
2 weeks of treatment over 8 weeks
|
Change From Baseline in Heart Rate as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint
Time Frame: Baseline, 2 weeks of treatment over 8 weeks
|
Change from baseline to the end of each of the 2-week treatment periods (Periods B, C, and D) for heart rate are presented.
Least Squares Mean (LSMean) values were adjusted for baseline and treatment.
|
Baseline, 2 weeks of treatment over 8 weeks
|
Change From Baseline in QT Interval Corrected Using Fridericia Formula (QTcF) as Measured by Electrocardiogram (ECG) at Each 2-week Treatment Endpoint
Time Frame: Baseline, 2 weeks of treatment over 8 weeks
|
QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.
QTcF is the QT interval corrected for heart rate using Fridericia formula.
Least Squares Mean (LSMean) values were adjusted for baseline and treatment.
|
Baseline, 2 weeks of treatment over 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
February 1, 2010
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
October 31, 2008
First Submitted That Met QC Criteria
October 31, 2008
First Posted (Estimate)
November 4, 2008
Study Record Updates
Last Update Posted (Estimate)
February 29, 2012
Last Update Submitted That Met QC Criteria
January 30, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Sleep Initiation and Maintenance Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Hypnotics and Sedatives
- GABA Agents
- Sleep Aids, Pharmaceutical
- GABA-A Receptor Agonists
- GABA Agonists
- Zolpidem
Other Study ID Numbers
- 12063
- I2K-MC-ZZAD (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Insomnia
-
Midnight Pharma, LLCCompletedChronic Primary InsomniaUnited States
-
Oregon Health and Science UniversityCompletedPrimary Insomnia | Psychophysiological InsomniaUnited States
-
University of RochesterSanofi-SynthelaboCompletedInsomnia | Primary Insomnia | Psychophysiologic InsomniaUnited States
-
IWK Health CentreUnknownPrimary Insomnia | Nonorganic InsomniaCanada
-
University of UtahEvans Army Community HospitalCompletedPrimary Insomnia | Secondary InsomniaUnited States
-
US Department of Veterans AffairsCompletedInsomnia | Primary Insomnia | Secondary InsomniaUnited States
-
Jack Edinger, PhDMerck Sharp & Dohme LLCCompletedInsomnia | Primary Insomnia | Chronic InsomniaUnited States
-
University of PittsburghCompletedInsomnia Chronic | Insomnia, PrimaryUnited States
-
University of WashingtonUnknownChronic Insomnia | Insomnia, Primary
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownPrimary Insomnia | Depressive Disorders With InsomniaTaiwan
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States